Search PubMed⌕ Search

Biomedical subjects

L Chedid

Publications and source records attributed to L Chedid.

At least 91 records · Page 5Linked to original sources
PubMed1984

Specific absorption with monoclonal antibodies to muramyl dipeptide of the pyrogenic and somnogenic activities of rabbit monokine.

It is well established that muramyl dipeptide (MDP) can induce fever and enhance slow-wave sleep. Recently, crude or purified supernatants of activated macrophages containing endogenous pyrogen (EP) were also shown to enhance slow-wave sleep. These similarities and the recent finding that a mammalian factor that enhances slow-wave sleep is a muramyl peptide triggered us to study the possibility of the presence of this bacterial structure in the EP molecule. In the present study, EP was produced by stimulation of rabbit peritoneal cells with a nonpyrogenic, nonsomnogenic analog of MDP. The EP-containing supernatant lost its pyrogenicity and somnogenicity after passage over an immunoadsorbent column of monoclonal anti-MDP but not of another monoclonal antibody of different specificity. High percentage of the EP was recovered by elution of the anti-MDP columns with HCl/glycine buffer. Results suggest that bacterial muramyl peptides may be incorporated by mammalian cells into substances that act in picomole quantities to mediate immunological and physiological processes. In addition, the technique may be useful to extract interleukin 1 for structural studies.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein.

The ability of chemically synthesized subpeptides of type 24 streptococcal M protein to evoke protective antibodies in rabbits was investigated. We synthesized copies of the COOH-terminal 13, 18, and 23 amino acid residues of cyanogen bromide fragment 7 (CB7) of pepsin-extracted type 24 M protein, except that methionine was substituted for homoserine as the COOH-terminal residue. An additional residue of cysteine was added at the COOH terminus of the 13-residue peptide. Each of the peptides, designated S-CB7-(23-35)-Cys, S-CB7-(18-35), and S-CB7-(13-35), when conjugated to lysylated tetanus toxoid with glutaraldehyde, was capable of stimulating formation of protective anti-type 24 M protein antibodies in rabbits. The smallest peptide, S-CB7-(23-35)-Cys, elicited immune responses equally as strong, if not stronger, than those to the longer peptides. A single Lys/Gly substitution in this 13-residue peptide resulted in its failure to stimulate protective antibodies. None of the antisera reacted with heterologous serotypes of M protein and none reacted with frozen sections of human heart tissue. These results indicate that a chemically synthesized peptide fragment corresponding to as few as 13 amino acid residues of streptococcal M protein is capable of evoking protective anti-streptococcal antibodies without evoking antibodies crossreactive with cardiac tissue.

Amino Acid Sequence↗
PubMed1984

Colony-stimulating activity induced by synthetic muramyl peptides: variation with chemical structure and association with anti-infectious activity.

The in vivo induction of colony-stimulating activity (CSA) by N-acetylmuramyl-L-alanine-D-isoglutamine has been demonstrated recently. In this study we increased our understanding of this property by testing muramyl peptides of several structures and activities for their capacity to induce CSA in vivo. A comparison of the anti-infectious and adjuvant activities of these molecules revealed no correlation between the capacities of these compounds to be adjuvant active and to induce CSA: all adjuvant-inactive compounds induced CSA, and certain adjuvant-active molecules did not induce CSA. In contrast, all anti-infectious compounds induced CSA, but the reverse was not true; some compounds devoid of anti-infection activity were able to induce CSA only if they were adjuvant active.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative.

N-acetylmuramyl-L-alanyl-D-isoglutamine, or muramyl dipeptide (MDP), is a synthetic immunoadjuvant analogue of a bacterial peptidoglycan subunit that has a definite pyrogenic effect in the rabbit. Some adjuvant-active derivatives such as murabutide [MDP(Gln)-OnBu] or murametide [MDP(Gln)-OMe] are not pyrogenic. Murabutide did not stimulate human or rabbit cells to release endogenous pyrogen (EP), but murametide induced EP production at the same dosage levels as MDP. Moreover, plasma from rabbits treated with murametide transferred into untreated recipients elicited a febrile response typical of EP fever and comparable with that induced by plasma from MDP-treated animals. Murametide not only inhibited the central effect of EP that is generated but also the effect of an extra dose of EP administered later by the intravenous route. Moreover, pretreatment of rabbits with murametide decreased fever responses induced by certain high-molecular-weight exogenous pyrogens as mediated through the production of EP.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Sleep-promoting effects of endogenous pyrogen (interleukin-1).

When infused into the lateral cerebral ventricles of rabbits, human endogenous pyrogen (EP) preparations induced dose-dependent increases in slow-wave sleep concomitant with increasing body temperature. Heating EP to 70 degrees C destroyed its sleep-promoting and pyrogenic activity. Anisomycin (an antipyretic) prevented EP from increasing body temperature without affecting its sleep-promoting activity. Intravenous injection of EP induced fever and transient increases in slow-wave sleep but failed to induce prolonged increases in slow-wave sleep. We conclude that the somnogenic activity of EP is not secondary to its pyrogenic activity.

Animals↗
PubMed1984

Smooth muscle stimulation by an immunomodulatory compound muramyl dipeptide: does it involve serotoninergic system?

Contractions evoked by muramyl dipeptide (MDP), a synthetic compound possessing immunostimulatory properties, were studied in several isolated nerve-smooth muscle preparations. The contractions by micromolar concentrations of MDP were evoked either by direct interaction with smooth muscle (rat stomach strip) or at least partly indirectly via neurogenic stimulation (guinea pig ileum); the effect was stereospecific since the MDP-D was not active. The insensitivity of the preparations to serotonin (5-HT), either inherent (vas deferens) or after 5-HT antagonists or after desensitization to 5-HT, prevented or markedly reduced the contractile activity by MDP. On the other hand, a nanomolar concentration of MDP enhanced the sensitivity of the rat stomach strip to 5-HT.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Adjuvant requirements for protective immunization of mice using a Trypanosoma cruzi 90K cell surface glycoprotein.

A wide range of adjuvants including alhydrogel, saponin, Corynebacterium parvum, DDAB, Pfizer CP-20,961, oil adjuvants and several MDP analogues have been compared for their adjuvant activity in protecting mice against lethal Trypanosoma cruzi infection following immunization with a T. cruzi 90K cell surface glycoprotein. Only saponin was found to be effective. Promotion did not correlate with the ability to promote a particular Ig isotype; however, saponin was unique in its ability to promote cell-mediate immunity against the 90K glycoprotein.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Inhibition of human IL 2 production by MDP and derivatives.

In the present study, well-defined immunomodulatory synthetic glycopeptides were used to investigate putative regulatory mechanisms of in vitro IL 2 production by normal human peripheral blood mononuclear cells. MDP (muramyl dipeptide) and two of its structural analogs, murabutide and MDP-DD, were shown to inhibit the in vitro PHA-induced IL 2 production in a majority of normal individuals tested. Involvement of prostaglandins in such an inhibitory effect was suggested by the fact that indomethacin completely abrogated the MDP-induced suppression. There was, however, some evidence indicating that the inhibition induced by the synthetic glycopeptides and that induced by PGE2 were somewhat different. Indeed, although the PGE2-induced suppression of IL 2 production was completely reversed by preirradiation of PBMNC, this was not observed for the MDP-dependent inhibition. In addition, PMA was able to abrogate the suppression induced by MDP, whereas it increased that of PGE2. From these data we propose that at least two independent pathways in the regulation of human IL 2 production exist: a one-signal pathway already described in which PGE2 directly triggers a radiosensitive suppressor T cell subset; and a second pathway with two signals, one given by PGE2 and a second one given by agents such as muramyl peptides. These two signals are required to activate a radioresistant suppressor cell subset.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Immunomodulation of macrophages by muramyl peptides: recent findings concerning somnogenic activity of muramyl peptides and monokine.

Synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine, also called MDP for muramyl dipeptide, is a copy of a fragment of bacterial peptidoglycan. MDP and several of its derivatives have marked immunological and pharmacological activities. Besides being adjuvants and capable of producing hyperthermia, they can also induce an increase of slow-wave sleep (SWS). It became apparent in the course of the investigations that in many cases the effects produced by MDP could be mediated by the macrophages. Therefore, after briefly reviewing their influence as macrophage activators, we will focus on certain newer findings such as the somnogenic activity of MDP and of monokine.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1984

Regulation by muramyl dipeptide (MDP) of the lymphoproliferative responses and polyclonal activation of human peripheral blood mononuclear cells.

The ability of muramyl dipeptide (MDP), its adjuvant inactive stereoisomer, MDP(D-D), and the non-pyrogenic, adjuvant active analogue, MDP-butyl ester (MDP-BE), to induce in vitro proliferation and/or polyclonal activation (PA) of peripheral blood mononuclear cells (PBMNC) from normal volunteers, was studied. MDP, as well as its two analogues, were incapable of inducing 3H-thymidine uptake or immunoglobulin synthesis in PBMNC cultures from the majority of the individuals tested. However, these muramyl peptides were capable of regulating the in vitro proliferative responses of some individuals to concanavalin A and to soluble antigens of Candida albicans. At the same time, enhancement of the pokeweed mitogen-induced IgA and IgM but not IgG PA was observed with MDP, its adjuvant active analogue MDP-BE, but not with the adjuvant inactive stereoisomer MDP(D-D). Results are discussed with relation to a possible genetic restriction of the responsiveness to MDP.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1983

Antibody responses elicited by a polyvalent vaccine containing synthetic diphtheric, streptococcal and hepatitis peptides coupled to the same carrier.

Three synthetic peptides copying fragments of the diphtheria toxin, the M protein of the streptococcus type 24 and the hepatitis B virus surface antigen (HBs) have been conjugated together to the tetanus toxoid. This polyvalent vaccine has been administered to mice. High antibody titers were obtained against the three antigens. No cross-reactivity could be observed between them as demonstrated by the ability of each peptide to inhibit only the antibodies against the natural M protein and the synthetic M protein peptide indicated that the avidity of the antibodies raised against a monovalent streptococcal vaccine were identical to those raised following injection of the polyvalent vaccine. Antibodies raised against the polyvalent streptococcal vaccine were also protective as shown by opsonophagocytic assays.

Animals↗
PubMed1983

Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant.

A polypeptide fragment of type 24 streptococcal M protein (pep M24) has been shown to raise protective anti-streptococcal antibodies in rabbits and humans when administered with adjuvants. More recently, such protective antibodies were shown to be evoked by a synthesized 35-residue sub-peptide fragment (S-CB7 synthetic cyanogen bromide fragment 7) of pep M24. We now show that the weak pep M24 immunogen induces high titers of long lasting antibodies when associated with murabutide, a synthetic derivative of MDP (NAcMur-L-Ala-D-Gln-n-butyl-ester) which is currently undergoing clinical trials. We demonstrate also that the polymerized synthetic S-CB7 administered without adjuvant or carrier evokes a strong epitope specific, protective immune response in mice primed with the parent pep M24. A booster dose of polymerized S-CB7 induced antibodies directed specifically against the S-CB7 structure whereas a booster dose of pep M24 evoked antibodies recognizing additional determinants of the whole pep M24 molecule.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1983

Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity.

Monoclonal antibodies to MDP were prepared by hybridization of NSO myeloma cells with spleen cells of BALB/c mice immunized with MDP conjugated to methyl-BSA. Hybridomas secreting anti-MDP antibodies were selected by the binding activity of their supernates to MDP-A--L using a radioimmunoassay. After cloning in soft agar, the specificities of monoclonal anti-MDP antibodies were assayed by an inhibition of ELISA with various derivatives of MDP. Fine structural analysis of specificity for one such clone (2-4) is reported. This antibody recognizes the N-acetyl-muramic acid (N-Ac-Mur) linked to the dipeptide but not N-Ac-Mur or/and dipeptide alone. The N-Ac group on muramic acid is an important antigenic determinant and the glycopeptide linkage seems to be crucial in presenting the sugar moiety. Conservative substitution of L-Ala (i.e. by L-Ser or L-Val) had no effect on the binding ability to the antibody whereas a radical change, i.e. replacement of L-Ala by L-Pro or N-methyl-L-Ala completely abolished the antigenicity of the molecule. There was no clear correlation between biological activities of various derivatives of MDP and their ability to react with this antibody. Some possible hypotheses explaining this lack of correlation are presented.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1983

Muramyl peptides as possible endogenous immunopharmacological mediators.

Synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine, also called MDP for muramyl dipeptide, is a copy of a fragment of bacterial peptidoglycan. Soon after the recognition of MDP as being the minimal subunit responsible for the activity of Freund's complete adjuvant, a great number of derivatives were synthesized. Because of their very low molecular weight it was hoped that they could retain selectively certain of the numerous effects produced by complex bacterial agents. Evidence was gathered showing MDP's direct effect on lymphocytes and on macrophages. The ensuing studies reviewed that MDP and several of its derivatives have marked immunopharmacological and neuropharmacological activities. Thus, besides being adjuvants, they are capable of producing hyperthermia by acting directly on thermoregulation centers or by inducing in vivo and in vitro endogenous pyrogens (EP). More recently, Krueger et al have shown that slow-wave sleep (SWS) factor was a muramyl peptide of a molecular weight close to 1,000 daltons. They have also shown that MDP and several of its synthetic analogs had a somnogenic activity. It has previously been hypothesized that several of the immunological activities of the muramyl peptides could be due to biological mimicry with endogenous products. Recent observations argue in favor of the presence of an MDP bacterial structure in mammalian mediators which increase slow-wave sleep and/or produce fever. The implications of these findings will be discussed.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1983

Amyloidosis and the serum amyloid A protein response to muramyl dipeptide analogs and different mycobacterial species.

Serum amyloid A protein (SAA) elevation accompanies induction of secondary amyloidosis in mice given Mycobacterium butyricum in Freund adjuvant. The synthesis of SAA by cultured hepatocytes is induced by a macrophage-derived mediator, which has been identified as interleukin 1. In these studies, SAA synthesis has been used as an index of macrophage activation to examine the in vivo response of mice to challenge with seven different mycobacteria and with synthetic analogs of the immunoadjuvant N-acetylmuramyl-L-alanyl-D-isoglutamine [MDP(L-D)]. SAA synthesis was stimulated by administration (by the intraperitoneal route) of the mycobacteria dissolved in saline, with Mycobacterium vaccae being the most active and Mycobacterium leprae being the least stimulatory. MDP(L-D), which is the minimal structure (molecular weight, 492) able to substitute for mycobacteria in Freund adjuvant, stimulated SAA synthesis, whereas the MDP(D-D) isomer was inactive. The butyl ester of MDP, which induces no detectable pyrogenicity but retains adjuvanticity, required a 100-fold greater dosage than MDP(L-D) in stimulating SAA synthesis. Amyloidosis was detected histologically only when active SAA inducers MDP(L-D), M. vaccae, and M. butyricum, were administered in incomplete Freund adjuvant, with amyloid-enhancing factor. These studies demonstrated that SAA elevation was a sensitive in vivo marker of the capacity of antigens to stimulate macrophages to produce interleukin 1. A point of considerable relevance to the human use of MDP was the observation that repeated injections of the adjuvant MDP in saline did not induce secondary amyloidosis.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1983

Modulation of myelopoiesis in vivo by synthetic adjuvant-active muramyl peptides: induction of colony-stimulating activity and stimulation of stem cell proliferation.

Modulation of myelopoiesis by three synthetic muramyl peptides was investigated in vivo. Two adjuvant-active compounds (N-acetylmuramyl dipeptide [MDP] and MDP-butyl-ester) elicited significant responses in DBA/2 mice characterized by a rise in the level of monocyte-macrophage colony-stimulating activity in serum, a proliferation of multipotential stem cells in the bone marrow, and an expansion of granulocyte-macrophage progenitors in the spleen. In contrast, the adjuvant-inactive stereoisomer MDP(D-D) induced only low levels of circulating colony-stimulating activity. Thus, MDP or MDP-butyl-ester injection could induce a greater number of macrophages and therefore enhance both specific and nonspecific immunity.

Acetylmuramyl-Alanyl-Isoglutamine↗